Building an effective malaria vaccine pipeline to address global needs

Vaccine

Volumn 33, Issue 52, 2015, Pages 7538-7543

  Birkett, Ashley J ^a  

^a PATH Malaria Vaccine Initiative   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

ARTICLE; CHEMOPROPHYLAXIS; FUNDING; HUMAN; IMMUNIZATION; MALARIA; MALARIA CONTROL; NONHUMAN; PARASITE DEVELOPMENT; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PUBLIC HEALTH; SPOROZOITE; VACCINE PRODUCTION; CLINICAL TRIAL (TOPIC); HEALTH; IMMUNOLOGY;

CLINICAL TRIALS AS TOPIC; GLOBAL HEALTH; HUMANS; MALARIA; MALARIA VACCINES;

EID: 84951908126     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.111     Document Type: Article

References (52)

1. WHO World Malaria Report. 2014.
2. A research agenda for malaria eradication: vaccines. PLoS Med 2011, 8(1):e1000398. The malERA Consultative Group on Vaccines.
3. Cohen J.M., Smith D.L., Cotter C., Ward A., Yamey G., Sabot O.J., et al. Malaria resurgence: a systematic review and assessment of its causes. Malar J 2012, 11:122.
4. White N.J., Pukrittayakamee S., Hien T.T., Faiz M.A., Mokuolu O.A., Dondorp A.M. Malaria. Lancet 2014, 383:723-735.
5. Moorthy V.S., Newman R.D., Okwo-Bele J.-M. Malaria Vaccine Technology Roadmap. Lancet 2013, 382:1700-1701.
6. Gessner B.D., Feikin D.R. Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy. Vaccine 2014, 32:3133-3138.
7. WHO. World Health Organization. Global plan for insecticide resistance management in malaria vectors (GPIRM). 2012.
8. WHO. Global plan for artemisinin resistance containment. 2011.
9. Ashley E.A., Dhorda M., Fairhurst R.M., Amaratunga C., Lim P., Suon S., et al. Spread of Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014, 371:411-423.
10. Ranson H., N'Guessan R., Lines J., Moiroux N., Nkuni Z., Corbel V. Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control?. Trends Parasitol 2011, 27:91-98.
11. WHO. WHO Preferred Product Characteristics for Malaria Vaccines 2015.
12. Penny M.A., Maire N., Studer A., Schapira A., Smith T.A. What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines. PLoS One 2008, 3:e3193.
13. EckhoffP.A., Bever C.A., Gerardin J., Wenger E.A. Fun with maths: exploring implications of mathematical models for malaria eradication. Malar J 2014, 13:486.
14. Blagborough A.M., Churcher T.S., Upton L.M., Ghani A.C., Gething P.W., Sinden R.E. Transmission-blocking interventions eliminate malaria from laboratory populations. Nat Commun 2013, 4:1812.
15. From pipeline to product: malaria R&D funding needs into the next decade 2013, PATH, PATH, Seattle.
16. Mueller I., Galinski M.R., Baird J.K., Carlton J.M., Kochar D.K., Alonso P.L., et al. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis 2009, 9:555-566.
17. Leach A., Vekemans J., Lievens M., Ofori-Anyinam O., Cahill C., Owusu-Agyei S., et al. Design of a phase III multicenter trial to evaluate the efficacy of the RTS, S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malar J 2011, 10:224.
18. WHO. Use of Placebos in Vaccine Trials. Geneva: 2013.
19. Birkett A.J., Moorthy V.S., Loucq C., Chitnis C.E., Kaslow D.C. Malaria vaccine R&D in the decade of vaccines: breakthroughs, challenges and opportunities. Vaccine 2013, 31:B233-B243. (Supple).
20. Delrieu I., Leboulleux D., Ivinson K., Gessner B.D. Design of a Phase III cluster randomized trial to assess the efficacy and safety of a malaria transmission blocking vaccine. Vaccine 2015, 33:1518-1526.
21. Nunes J.K., Woods C., Carter T., Raphael T., Morin M.J., Diallo D., et al. Development of a transmission-blocking malaria vaccine: Progress, challenges, and the path forward. Vaccine 2014, 32:5531-5539.
22. Outcomes of the first WHO Product Development for Vaccines Advisory Committee meeting. Geneva: 2014.
23. Sauerwein R.W., Roestenberg M., Moorthy V.S. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011, 11:57-64.
24. Spring M., Polhemus M., Ockenhouse C. Controlled human malaria infection. J Infect Dis 2014, 209:S40-S45.
25. Roestenberg M., O'Hara G.A., Duncan C.J.A., Epstein J.E., Edwards N.J., Scholzen A., et al. Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One 2012, 7(6):e38434.
26. Cohen J., Nussenzweig V., Nussenzweig R., Vekemans J., Leach A. From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Hum Vaccin 2010, 6:90-96.
27. Bennett JW, Yadava A, Tosh D, Sattabongkot J, Komisar J, Cowden J, et al. Phase 1/2a open-label dose safety, reactogen- icity, immunogenicity and efficacy of the candidate Plasmodium vivax malaria protein 001 (VMP001) administered intramuscularly with GSK Biologicals' Adjuvant System AS01B in healthy malaria-naïve adults. ASTMH Annu. Meet. (Abstract 953), 2011.
28. Herrera S., Fernández O., Manzano M.R., Murrain B., Vergara J., Blanco P., et al. Case report: successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors. Am J Trop Med Hyg 2009, 81:740-746.
29. Sheehy S.H., Spencer A.J., Douglas A.D., Sim B.K.L., Longley R.J., Edwards N.J., et al. Optimising controlled human malaria infection studies using cryopreserved P. falciparum parasites administered by needle and syringe. PLoS One 2013, 8(6):e65960.
30. Roestenberg M., Bijker E.M., Sim B.K.L., Billingsley P.F., James E.R., Bastiaens G.J.H., et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2013, 88:5-13.
31. Hodgson S.H., Juma E., Salim A., Magiri C., Kimani D., Njenga D., et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol 2014, 5:686.
32. Shekalaghe S., Rutaihwa M., Billingsley P.F., Chemba M., Daubenberger C.A., James E., et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2014, 91(3):471-480.
33. Vanderberg J.P. Imaging mosquito transmission of Plasmodium sporozoites into the mammalian host: immunological implications. Parasitol Int 2014, 63:150-164.
34. Cheng Q., Lawrence G., Reed C., Stowers A., Ranford-Cartwright L., Creasey A., et al. Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am J Trop Med Hyg 1997, 57:495-500.
35. Duncan C.J., Draper S.J. Controlled human blood stage malaria infection: current status and potential applications. Am J Trop Med Hyg 2012, 86:561-565.
36. Sanderson F., Andrews L., Douglas A.D., Hunt-Cooke A., Bejon P., Hill A.V.S. Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. Am J Trop Med Hyg 2008, 78:878-883.
37. Duncan C.J., Sheehy S.H., Ewer K.J., Douglas A.D., Collins K.A., Halstead F.D., et al. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel + CPG 7909. PLoS One 2011, 6(7):e22271.
38. Thera M.A., Doumbo O.K., Coulibaly D., Laurens M.B., Ouattara A., Kone A.K., et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med 2011, 365:1004-1013.
39. Payne RO, Milne KH, Elias SC, Edwards NJ, Douglas AD, Brown RE, et al. A Phase I/IIa Study of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium falciparum, using Blood-Stage Controlled Malaria Human Malaria Infection. ASTMH 2014 Annual Meeting (Abstract LB-3120).
40. McCarthy J.S., Griffin P.M., Sekuloski S., Bright A.T., Rockett R., Looke D., et al. Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J Infect Dis 2013, 208:1688-1694.
41. Collins W.E., Jeffery G.M., Roberts J.M. A retrospective examination of the effect of fever and microgametocyte count on mosquito infection on humans infected with Plasmodium vivax. Am J Trop Med Hyg 2004, 70:638-641.
42. Bousema T., Dinglasan R.R., Morlais I., Gouagna L.C., van Warmerdam T., Awono-Ambene P.H., et al. Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. PLoS One 2012, 7:e42821.
43. Schwartz L., Brown G.V., Genton B., Moorthy V.S. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J 2012, 11:11.
44. Seder R.A., Chang L.-J., Enama M.E., Zephir K.L., Sarwar U.N., Gordon I.J., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341:1359-1365.
45. Spring M., Murphy J., Nielsen R., Dowler M., Bennett J.W., Zarling S., et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 2013, 31:4975-4983.
46. Van Schaijk B.C.L., Ploemen I.H.J., Annoura T., Vos M.W., Foquet L., van Gemert G.J., et al. A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites. eLife 2014, 3:e03582. (White NJ, ed.).
47. Mikolajczak S.A., Lakshmanan V., Fishbaugher M., Camargo N., Harupa A., Kaushansky A., et al. A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol Ther 2014, 22:1707-1715.
48. Fried M., Avril M., Chaturvedi R., Fernandez P., Lograsso J., Narum D., et al. Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria. Infect Immun 2013, 81:487-495.
49. Bergmann-Leitner E.S., Mease R.M., De La Vega P., Savranskaya T., Polhemus M., Ockenhouse C., et al. Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against Heterologous Challenge with Plasmodium berghei. PLoS One 2010, 5(8):e12294.
50. Douglas A.D., Williams A.R., Illingworth J.J., Kamuyu G., Biswas S., Goodman A.L., et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun 2011, 2:601.
51. Roestenberg M., Teirlinck A.C., McCall M.B.B., Teelen K., Makamdop K.N., Wiersma J., et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011, 377:1770-1776.
52. Roestenberg M., McCall M., Hopman J., Wiersma J., Luty A.J.F., van Gemert G.J., et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009, 361:468-477.